Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

por Usmani, Saad Z., Nahi, Hareth, Legiec, Wojciech, Grosicki, Sebastian, Vorobyev, Vladimir, Spicka, Ivan, Hungria, Vania, Korenkova, Sibirina, Bahlis, Nizar J., Flogegard, Max, Bladé, Joan, Moreau, Philippe, Kaiser, Martin, Iida, Shinsuke, Laubach, Jacob, Magen, Hila, Cavo, Michele, Hulin, Cyrille, White, Darrell, De Stefano, Valerio, Lantz, Kristen, O’Rourke, Lisa, Heuck, Christoph, Delioukina, Maria, Qin, Xiang, Nnane, Ivo, Qi, Ming, Mateos, Maria-Victoria
Publicado 2022